Pharmaceutical companies that fought drug pricing reforms Congress passed as part of the Inflation Reduction Act are now weighing a legal challenge as the Biden administration sets about implementing the policy.
PhRMA, the industry's big Washington trade group, says the Centers for Medicare and Medicaid Services rushed guidance on negotiations out the door. Additionally, the agency should have let stakeholders comment on an already-final section about which medications would be affected.submitted to regulators, and even argues that elements of the policy would violate the First Amendment if finalized as proposed."CMS cares a lot more about punishing us ...
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: